Document Type: Research Paper
Department of Biotechnology, College of science, The University of Tehran, Tehran, Iran.
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Department of Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
Background: Etanercept is prescribed for the rapid and effective treatment of chronic immune-mediated inflammatory disorders. Due to the expiration of etanercept patents and worldwide demand for comparable and more affordable substitutes, several biosimilars of etanercept have been approved in different countries and new ones are in the process of approval.
Objectives: In the present study, Altebrel™ as an etanercept proposed biosimilar was investigated in a side by side comparison using various orthogonal analytical methods.
Materials and Methods: Three batches of the Altebrel™ and Enbrel® samples were used for the study. Several physicochemical properties of samples were compared according to international guidelines. They included SDS-PAGE, CE-SDS, SE-HPLC, HIC-HPLC and its biological activity was evaluated using surface plasmon resonance affinity analysis and TNFα neutralization biological assay. Amino acid analysis was applied to check the primary sequence and far-UV CD spectroscopy investigated the secondary structure.
Results: The obtained results indicated a high degree of similarity between Altebrel™ and Enbrel®. Results of SDS-PAGE, CE-SDS, HIC-HPLC and SE-HPLC implied a comparable pattern of size variants for all samples. Based on the data achieved via in vitro bioactivity assays and SPR analysis, the functional property of Altebrel™ was proved comparable to that of the reference product. Moreover, amino acid analysis indicated similar primary structure and circular dichroism study implied a similar secondary structure for Altebrel™ and Enbrel®.
Conclusions: Overall, our data provide analytical evidence for structural and in vitro functional similarity between Altebrel™ and Enbrel®.